Holistic Treatment of Patients with HRpos HER2neg MBC and Comorbidities

CME

Treating the Whole Patient: Understanding Needs of Patients With HR-Positive/HER2-Negative MBC and Comorbidities

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: March 07, 2025

Expiration: September 06, 2025

Activity

Progress
1 2
Course Completed

Overall Conclusions

Overall, the use of CDK4/6 inhibitors in the treatment of patients with HR-positive, HER2-negative ABC has significantly improved patient outcomes. These agents are currently the gold standard of care for the first-line management of patients with HR-positive, HER2-negative MBC. Selecting among these 3 agents should involve a nuanced discussion with the patient regarding the efficacy and safety data and the potential for interactions with other medications. Ultimately, treatment decisions should be made in concert with the patient's goals of care and wishes.

Of note, some patients will remain on CDK4/6 inhibitors for many years. Thus, it is important to carefully educate them from the onset regarding the potential AEs and risks associated when used alone or in combination with other therapies. Healthcare professionals should not hesitate to involve the expertise of a multidisciplinary team, including pharmacists, palliative care providers, and relevant subspecialty colleagues to optimally manage patients in this setting.

How confident are you in planning communication strategies and utilizing shared decision-making to optimize patient–physician trust and understand patient goals when selecting MBC treatment?